Publication:
Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease.

dc.contributor.authorLeón Jiménez, David
dc.contributor.authorCherney, David Z I
dc.contributor.authorBjornstad, Petter
dc.contributor.authorCastilla-Guerra, Luis
dc.contributor.authorMiramontes González, José Pablo
dc.date.accessioned2023-01-25T10:21:12Z
dc.date.available2023-01-25T10:21:12Z
dc.date.issued2018-08-01
dc.description.abstractWhile sodium-glucose cotransporter-2 (SGLT2) inhibitors have been used for the routine management of type 2 diabetes for several years, it is perhaps their natriuretic effects that are most important clinically. This natriuresis activates tubuloglomerular feedback, resulting in reduced glomerular hypertension and proteinuria, leading to renal protective effects in the EMPA-REG OUTCOME and CANVAS Program trials. In the cardiovascular system, it is likely that plasma volume contraction due to natriuresis in response to SGLT2 inhibition is at least in part responsible for the reduction in the risk of heart failure observed in these trials. We compare this mechanism of action with other antidiabetics. Importantly, other diuretic classes, including thiazide and loop diuretics, have not resulted in such robust clinical benefits in patients with type 2 diabetes, possibly because these older agents do not influence intraglomerular pressure directly. In contrast, SGLT2 inhibitors do have important physiological similarities with carbonic anhydrase inhibitors, which also act proximally, and have been shown to activate tubuloglomerular feedback.
dc.identifier.doi10.1152/ajprenal.00384.2017
dc.identifier.essn1522-1466
dc.identifier.pmcPMC6293300
dc.identifier.pmid30066584
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293300/pdf
dc.identifier.unpaywallURLhttps://journals.physiology.org/doi/pdf/10.1152/ajprenal.00384.2017
dc.identifier.urihttp://hdl.handle.net/10668/12786
dc.issue.number5
dc.journal.titleAmerican journal of physiology. Renal physiology
dc.journal.titleabbreviationAm J Physiol Renal Physiol
dc.language.isoen
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationHospital Universitario Virgen Macarena
dc.page.numberF1406-F1415
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, N.I.H., Extramural
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.pubmedtypeReview
dc.rights.accessRightsopen access
dc.subjectalbuminuria
dc.subjectanhidrasa carbonic
dc.subjectdiabetic kidney disease
dc.subjectnatriuresis
dc.subjectsodium glucose type 2 inhibitor
dc.subject.meshAnimals
dc.subject.meshBiomarkers
dc.subject.meshBlood Glucose
dc.subject.meshDiabetes Mellitus, Type 2
dc.subject.meshDiabetic Nephropathies
dc.subject.meshDipeptidyl-Peptidase IV Inhibitors
dc.subject.meshHumans
dc.subject.meshIncretins
dc.subject.meshKidney
dc.subject.meshNatriuresis
dc.subject.meshSodium-Glucose Transporter 2
dc.subject.meshSodium-Glucose Transporter 2 Inhibitors
dc.subject.meshTreatment Outcome
dc.titleAntihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number315
dspace.entity.typePublication

Files